NASDAQ$KALV
KalVista Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
KalVista reported first fiscal quarter results and provided an operational update.
KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2024. Net loss was $40.4 million, or $(0.87) per share. Cash, cash equivalents, and marketable securities were $174.3 million on July 31, 2024.
- FDA accepted NDA for sebetralstat with a PDUFA goal date of June 17, 2025.
- EMA validated the submission of Marketing Authorization Application (MAA) for sebetralstat.
- KalVista expects to file for approval in the UK, Japan, and other countries later in 2024.
- A pediatric clinical trial (KONFIDENT-KID) using an orally disintegrating tablet (ODT) formulation of sebetralstat designed for this population was initiated.
Headline financials
Revenue & EPS history
KalVista · Revenue · Quarterly
$0
Forward guidance
KalVista expects to file for approval in the UK, Japan, and other countries later in 2024 and aim for their first commercial launch of sebetralstat in June 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.3%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+20.3%
Q4 2018
Best reaction
-26.3%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +1.1% | +26.3% | +56.4% | |
| Q1 2026 | -3.8% | -12.3% | -25.3% | |
| Q4 2025 | -3.1% | -5.1% | -22.4% | |
| Q3 2025 | +2.0% | -2.6% | +5.1% | |
| Q2 2025 | -4.2% | -0.2% | -4.5% | |
| Q1 2025 | -4.5% | -13.2% | -12.1% | |
| Q4 2024 | +3.7% | +21.3% | +2.6% | |
| Q3 2024 | -13.0% | -16.9% | -16.9% | |
| Q2 2024 | -9.0% | +8.8% | +26.8% | |
| Q1 2024 | -4.0% | -4.2% | -12.2% | |
| Q4 2023 | +17.0% | +7.6% | +23.5% | |
| Q3 2023 | -10.4% | -1.3% | +2.7% | |
| Q2 2023 | +9.8% | +7.3% | +27.8% | |
| Q1 2023 | +1.4% | -2.5% | -68.4% | |
| Q4 2022 | +10.6% | +18.0% | +37.5% | |
| Q3 2022 | -9.3% | -14.6% | -16.4% | |
| Q2 2022 | -0.4% | -2.9% | -4.2% | |
| Q1 2022 | -0.6% | -6.0% | -14.4% | |
| Q4 2021 | -3.0% | -2.9% | -14.0% | |
| Q3 2021 | +3.4% | +8.9% | -16.8% | |
| Q2 2021 | +5.2% | +5.1% | -7.0% | |
| Q1 2021 | +2.0% | +1.3% | +9.8% | |
| Q4 2020 | +7.2% | +4.2% | -18.8% | |
| Q3 2020 | -26.3% | -41.2% | -20.9% | |
| Q2 2020 | -1.8% | -5.7% | +18.9% | |
| Q1 2020 | +8.7% | +1.0% | -29.4% | |
| Q4 2019 | -0.5% | +1.4% | -6.7% | |
| Q3 2019 | +10.4% | +7.6% | -0.2% | |
| Q2 2019 | -14.0% | -21.2% | -15.5% | |
| Q1 2019 | +9.6% | +4.6% | +20.6% | |
| Q4 2018 | +20.3% | +29.8% | +94.0% | |
| Q3 2018 | +4.7% | +11.7% | +0.8% | |
| Q2 2018 | -4.8% | -12.3% | +0.2% | |
| Q1 2018 | -21.5% | -23.6% | +9.8% | |
| Q4 2017 | -0.8% | -2.7% | -11.6% | |
| Q3 2017 | +1.9% | -1.0% | -12.2% | |
| Q2 2017 | -1.9% | -2.9% | -1.6% | |
| Q1 2017 | +0.4% | +13.1% | -13.3% | |
| Q4 2016 | -3.2% | — | — | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | -3.2% | — | — | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro